| Literature DB >> 31391087 |
Shirong Zhang1,2, Xiaochen Zhang3, Wei Lei4, Jiafeng Liang1, Yasi Xu1, Hailiang Liu5, Shenglin Ma6,7.
Abstract
BACKGROUND: Lung cancer is the second most common cancer with an extremely poor overall survival rate. Post-transcriptional regulation of gene expression play many important roles in human cancer, and one of the potential mechanisms underlying this is alternative mRNA maturation at its 3' untranslated regions (3'-UTRs).Entities:
Keywords: 3′UTR; CSTF2; Lung cancer; Poly(A) processing
Mesh:
Substances:
Year: 2019 PMID: 31391087 PMCID: PMC6686416 DOI: 10.1186/s12967-019-1986-0
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
The clinical information about 26 patient diagnosed with NSCLC
| No. | Sex | Age (years) | Smoking history (per month) | Pathologic type | TNM classification | Clinical stage |
|---|---|---|---|---|---|---|
| 1 | Women | 73 | No | Adenocarcinoma | T2aN1M0 | IIB |
| 2 | Men | 76 | Yes | Adenocarcinoma | T2aN2M0 | IIIA |
| 3 | Men | 66 | Yes | Adenocarcinoma | T2aN0M0 | IB |
| 4 | Men | 67 | No | Squamous | T1cN0M0 | IA |
| 5 | Women | 62 | No | Adenocarcinoma | T2aN1M0 | IIB |
| 6 | Women | 72 | No | Adenocarcinoma | T2aN1M0 | IIB |
| 7 | Women | 78 | No | Squamous | T2aN2M0 | IIIA |
| 8 | Women | 67 | No | Squamous | T2aN0M0 | IB |
| 9 | Man | 49 | Yes | Squamous | T4N0M0 | IIIA |
| 10 | Women | 63 | No | Adenocarcinoma | T4N1M0 | IIIA |
| 11 | Man | 81 | Yes | Adenocarcinoma | T2aN2M0 | IIIA |
| 12 | Man | 60 | Yes | Adenocarcinoma | T2N2M0 | IIIA |
| 13 | Man | 59 | Yes | Adenocarcinoma | T2aN0M0 | IB |
| 14 | Women | 49 | No | Adenocarcinoma | T2N2M0 | IIIA |
| 15 | Women | 74 | No | Adenocarcinoma | T2aN0M0 | IB |
| 16 | Man | 55 | Yes | Adenocarcinoma | T1cN0M0 | IA |
| 17 | Women | 64 | No | Adenocarcinoma | T2aN2M0 | IIIA |
| 18 | Man | 79 | No | Adenocarcinoma | T1bN0M0 | IA |
| 19 | Man | 69 | Yes | Squamous | T3N1M0 | IIIA |
| 20 | Man | 49 | Yes | Squamous | T1bN0M0 | IA |
| 21 | Man | 63 | No | Adenocarcinoma | T1cN1M0 | IIB |
| 22 | Man | 54 | Yes | Adenocarcinoma | T2N2M0 | IIIA |
| 23 | Women | 71 | No | Adenocarcinoma | T2aN1M0 | IIB |
| 24 | Man | 47 | No | Adenocarcinoma | T1bN0M0 | IA |
| 25 | Man | 61 | Yes | Squamous | T1cN2M0 | IIIA |
| 26 | Women | 58 | No | Squamous | T2aN0M0 | IB |
Fig. 1Characteristics of poly(A) sites. The reads and poly(A) sites were first mapped to the known sites of UCSC and Tiaqn’s poly(A) database, and the unmapped reads were annotated to 3′UTR, intron, CDS, 1 kb-downstream and intergenic region. a Pie-chart of mapping location of reads. b Volcano plot for DEGs. c KEGG enrichment analysis for up-regulated genes in cancer tissues. d KEGG enrichment analysis for down-regulated genes in cancer tissues
Fig. 2Differentially expressed genes in NSCLC tissue and paired para-carcinoma tissues and DAVID program-based functional annotation. a Comparison of the tandem 3′UTR standardized lengths of lung cancer tissue and paired para-carcinoma tissue from 26 pairs of clinical samples. Orange: cancer tissues. Blue: paired para-carcinoma tissues. b Enrichment of genes with significantly shorter 3′UTR isoforms involved in KEGG categories. c Enrichment of genes with significantly shorter 3′UTR isoforms involved in GO functional analysis
Fig. 3CSTF2 expression in lung cancer cells. a Log2 results for ratio of the gene expression level between cancer and para-carcinoma tissue of 93 RNA transcription and translation related influential factors. Red colored bars represented the genes with significantly up-regulated expression (p < 0.01) in cancer tissue. Blue colored bars represented the genes with significantly down-regulated expression (p < 0.01) in cancer tissue. b Western blot analysis showing the CSTF2 protein levels of lung cancer cell lines and normal lung HFL1 cell line. c Graph showing the higher mRNA expression of CSTF2 detected in the H460 compared to HFL1 cells. Data represents the average of three independent q-RT-PCR experiment. d Log2 results for ratio of CSTF2 gene expression detected in our clinical samples and summarized from TCGA database
Fig. 4CSTF2 regulates 3′UTR shortening of genes in NSCLC cell. a siRNA transduction reduces the mRNA (left) and protein (right) levels of CSTF2 gene in H460 cells. b Comparison of distribution pattern for poly(A) signals in data sets of clinical samples and H460 cells. c Profiling of 60 genes with elongated 3′UTR length in H460 cells with knocking-down of CSTF2 expression. d Profiling of 18 genes with shortened 3′UTR length in H460 cells with knocking-down of CSTF2 expression. e Venn diagram for comparison between overlapped genes detected in data sets of H460 cells and clinical samples
KEGG pathway analysis of 38 overlapping genes in si-CSTF2 cell line
| UCSC ID | Gene name | KEGG_PATHWAY |
|---|---|---|
| uc001dlw.2 | SH3-domain GRB2-like endophilin B1 | hsa04144:Endocytosis |
| uc001kta.2 | Beta-transducin repeat containing | hsa04114:Oocyte meiosis, hsa04120:Ubiquitin mediated proteolysis, hsa04310:Wnt signaling pathway, hsa04340:Hedgehog signaling pathway |
| uc002pew.2 | Calmodulin 3 (phosphorylase kinase, delta); calmodulin 2 (phosphorylase kinase, delta); calmodulin 1 (phosphorylase kinase, delta) | hsa04020:Calcium signaling pathway, hsa04070:Phosphatidylinositol signaling system, hsa04114:Oocyte meiosis, hsa04270:Vascular smooth muscle contraction, hsa04720:Long-term potentiation, hsa04722:Neurotrophin signaling pathway, hsa04740:Olfactory transduction, hsa04910:Insulin signaling pathway, hsa04912:GnRH signaling pathway, hsa04916:Melanogenesis, hsa05010:Alzheimer’s disease, hsa05214:Glioma |
| uc003iev.1 | Fibroblast growth factor 2 (basic) | hsa04010:MAPK signaling pathway, hsa04810:Regulation of actin cytoskeleton, hsa05200:Pathways in cancer, hsa05218:Melanoma |
| uc002tbc.2 | Mitogen-activated protein kinase kinase kinase kinase 4 | hsa04010:MAPK signaling pathway |
| uc003hzp.2 | Phospholipase A2, group XIIA | hsa00564:Glycerophospholipid metabolism, hsa00565:Ether lipid metabolism, hsa00590:Arachidonic acid metabolism, hsa00591:Linoleic acid metabolism, hsa00592:alpha-Linolenic acid metabolism, hsa04010:MAPK signaling pathway, hsa04270:Vascular smooth muscle contraction, hsa04370:VEGF signaling pathway, hsa04664:Fc epsilon RI signaling pathway, hsa04730:Long-term depression, hsa04912:GnRH signaling pathway |
| uc003hbs.1 | Phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase | hsa00230:Purine metabolism |
| uc002fuw.3 | Platelet-activating factor acetylhydrolase, isoform Ib, subunit 1 (45 kDa) | hsa00565:Ether lipid metabolism |
| uc002jhg.2 | Protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) | hsa04210:Apoptosis, hsa04910:Insulin signaling pathway, |
| uc004czg.3 | Pyruvate dehydrogenase (lipoamide) alpha 1 | hsa00010:Glycolysis/Gluconeogenesis, hsa00020:Citrate cycle (TCA cycle), hsa00290:Valine, leucine and isoleucine biosynthesis, hsa00620:Pyruvate metabolism, hsa00650:Butanoate metabolism, |
| uc001xbo.2 | Suppressor of cytokine signaling 4 | hsa04630:Jak-STAT signaling pathway, hsa04910:Insulin signaling pathway, hsa04930:Type II diabetes mellitus |